Brokerages Set GlaxoSmithKline plc (GSK) Price Target at $1,620.31
Shares of GlaxoSmithKline plc (LON:GSK) have earned an average recommendation of “Hold” from the twenty research firms that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have given a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is GBX 1,620.31 ($21.17).
Several analysts have recently weighed in on GSK shares. UBS Group set a GBX 1,700 ($22.21) price objective on GlaxoSmithKline and gave the company a “buy” rating in a report on Wednesday, January 2nd. Deutsche Bank set a GBX 1,520 ($19.86) price objective on GlaxoSmithKline and gave the company a “neutral” rating in a report on Tuesday, January 1st. Goldman Sachs Group set a GBX 1,900 ($24.83) price objective on GlaxoSmithKline and gave the company a “buy” rating in a report on Monday, December 31st. Shore Capital reaffirmed a “buy” rating on shares of GlaxoSmithKline in a research report on Wednesday, December 19th. Finally, Liberum Capital reaffirmed a “hold” rating and set a GBX 1,700 ($22.21) target price on shares of GlaxoSmithKline in a research report on Wednesday, December 19th.
GSK stock traded down GBX 10.80 ($0.14) during trading on Friday, reaching GBX 1,525.20 ($19.93). 7,186,627 shares of the company’s stock were exchanged, compared to its average volume of 9,120,000. GlaxoSmithKline has a 1-year low of GBX 1,235.20 ($16.14) and a 1-year high of GBX 1,724.50 ($22.53).
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Recommended Story: Short Selling Stocks and Day Traders
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.